focus -WSS

focus

author：hotspot 2025-09-04 22:14:56 - browse：187

A doctor climbs up a red ladder to a vine shaped like a DNA — biotech coverage from STAT — Adobe

Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the hall, and helps her 8-year-old daughter Addi slide into a set of contraptions that squeeze and suck out the thick mucus constantly threatening to choke her airways closed. She feeds Addi breakfast through a stomach tube and makes sure she has the right mix of the 28 different medications required to keep her free of pain, infections, and seizures. At some point, Rasberry’s five other children will wake up and start to get ready for school, including her youngest, Oliver. At 3-and-a-half years old, he’s a typical toddler — always running and giggling and getting into things. You would never know that he and Addi were born with the same mutation lurking in their DNA, a genetic glitch that causes a fatal neurodegenerative disease called metachromatic leukodystrophy, or MLD.

“When Addi was this age she had lost the ability to speak and was already using a ventilator to sleep at night,” Rasberry said. “It’s amazing to see how well Ollie is doing in comparison. And it’s all because of the gene therapy.”

Three years ago, when Ollie was just 6 months old, he and Victoria traveled from their home in Texas to Milan, to receive a gene therapy treatment that adds a healthy version of the defective gene into patients’ own stem cells. At the time, traveling abroad for the therapy, which is manufactured by Orchard Therapeutics and was approved in Europe in 2021, was the only option for families stricken by MLD. But soon it will be available in the U.S., too.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： CZI to create biohub to build anti

WSS

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Study on Amgen’s bispecific immunotherapy produces positive data

J&J lung cancer data amount to new salvo against AstraZeneca

Curing rare childhood diseases will falter unless Congress steps up

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

explore

focus

explore

New air purifier tech could be key to improving indoor air quality

Cheap, fast test for Zika and dengue could cost just $1

How to save PrEP access — and even expand it

Curing rare childhood diseases will falter unless Congress steps up

Continuity nursing helped my family in our darkest PICU moments

Why a market frenzy over new weight loss drugs defies logic

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: Live from the 2023 STAT Summit

Trump demands the U.S. pay no more for drugs than other countries … again

STAT Virtual Event: ASCO Recap, Live!

focus

ADCs take center stage as promising cancer treatments

'Essentially witchcraft:' A former naturopath takes on the field

Report captures long Covid’s disabling effects and policy challenges

Coercive sterilizations revealed by STAT prompt outrage

Roivant's CEO is a star, but biotech's black hole persists

Health care court cases: Humana, Sutter, Novant

focus

knowledge

hotspot

knowledge